Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 2
2013 2
2015 1
2016 3
2017 3
2018 2
2019 2
2020 2
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

18 results
Results by year
Filters applied: . Clear all
Page 1
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, Leutz B, Adamia S, Zhu H, Kuang Y, Mogili A, Louissaint A Jr, Bohl SR, Kim AS, Mehta AK, Sanghavi S, Wang Y, Morris E, Halilovic E, Paweletz CP, Weinstock DM, Garcia JS, Letai A. Bhatt S, et al. Cancer Cell. 2020 Dec 14;38(6):872-890.e6. doi: 10.1016/j.ccell.2020.10.010. Epub 2020 Nov 19. Cancer Cell. 2020. PMID: 33217342
Inhibition of USP10 induces degradation of oncogenic FLT3.
Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, Adamia S, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, Buhrlage SJ. Weisberg EL, et al. Among authors: bhatt s. Nat Chem Biol. 2017 Dec;13(12):1207-1215. doi: 10.1038/nchembio.2486. Epub 2017 Oct 2. Nat Chem Biol. 2017. PMID: 28967922 Free PMC article.
PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells.
Kahn JD, Miller PG, Silver AJ, Sellar RS, Bhatt S, Gibson C, McConkey M, Adams D, Mar B, Mertins P, Fereshetian S, Krug K, Zhu H, Letai A, Carr SA, Doench J, Jaiswal S, Ebert BL. Kahn JD, et al. Among authors: bhatt s. Blood. 2018 Sep 13;132(11):1095-1105. doi: 10.1182/blood-2018-05-850339. Epub 2018 Jun 28. Blood. 2018. PMID: 29954749 Free PMC article.
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.
Garcia JS, Bhatt S, Fell G, Sperling AS, Burgess M, Keshishian H, Yilma B, Brunner A, Neuberg D, Carr SA, Ebert BL, Ballen K, Stone RM, DeAngelo DJ, Medeiros BC, Letai A. Garcia JS, et al. Among authors: bhatt s. Am J Hematol. 2020 Mar;95(3):245-250. doi: 10.1002/ajh.25692. Epub 2019 Dec 22. Am J Hematol. 2020. PMID: 31804723 Free article. Clinical Trial.
Statins enhance efficacy of venetoclax in blood cancers.
Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA. Lee JS, et al. Among authors: bhatt s. Sci Transl Med. 2018 Jun 13;10(445):eaaq1240. doi: 10.1126/scitranslmed.aaq1240. Sci Transl Med. 2018. PMID: 29899021 Free PMC article.
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs.
Sperling AS, Burgess M, Keshishian H, Gasser JA, Bhatt S, Jan M, Słabicki M, Sellar RS, Fink EC, Miller PG, Liddicoat BJ, Sievers QL, Sharma R, Adams DN, Olesinski EA, Fulciniti M, Udeshi ND, Kuhn E, Letai A, Munshi NC, Carr SA, Ebert BL. Sperling AS, et al. Among authors: bhatt s. Blood. 2019 Jul 11;134(2):160-170. doi: 10.1182/blood.2019000789. Epub 2019 May 1. Blood. 2019. PMID: 31043423 Free PMC article.
18 results